The FDA and the European Medicines Agency are investigating a possible link between Genentech's psoriasis drug Raptiva and progressive multifocal leukoencephalopathy, a deadly brain infection. The agencies received three reports of deaths and one possible case of the disease. Genentech and its European partner Merck KGaA said they are working with the regulators to address the issue.

Related Summaries